A nonprofit led by a teacher and minister with limb-girdle MD again is offering postgraduate scholarships and small quality-of-life grants

posted on April 8, 2011 - 4:57pm
(Update 9/14/11: The 2011 scholarship winners have been selected. To view a list of winners visit Applications for quality of life grants continue to be accepted and are awarded on an ongoing basis.)

Winners with ALS, SMA and LGMD receive support to pursue postgraduate education

posted on September 17, 2010 - 2:29pm
Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships. “We were so impressed,” with the winning candidates, said Deshae Lott, 39, a teacher and minster from Bossier City, La., who founded the nonprofit that bears her name. “These three show great strength of...

News on amyotrophic lateral sclerosis, congenital muscular dystrophy, Friedreich's ataxia and spinal muscular atrophy

posted on August 27, 2010 - 11:20am
Amyotrophic lateral sclerosis (ALS)

Reports on research in amyotrophic lateral sclerosis, Duchenne muscular dystrophy, myotubular myopathy and spinal muscular atrophy

posted on August 12, 2010 - 11:33am
Duchenne muscular dystrophy Acceleron Pharma announced Aug. 4 that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its experimental compound ACE031 for the treatment of Duchenne muscular dystrophy (DMD). ACE031 is designed to interfere with the actions of myostatin, a protein that inhibits muscle growth.

Researchers have identified a compound that helps cells produce more full-length SMN protein from the backup SMN2 gene.

posted on November 6, 2009 - 1:19pm
Scientists have identified a chemical cousin of the commonly used antibiotic tetracycline that has the potential to be refined and modified into a therapy for spinal muscular atrophy (SMA). PTK-SMA1 works by correcting an error in a cellular process called RNA splicing, and leads to increased production of a critical protein that is deficient in this disease.

 A variant in the SMN2 gene leads to more full-length SMN protein and better function

posted on September 29, 2009 - 10:46am
Scientists have uncovered a variant (mutation) in the SMN2 gene that leads to production of more full-length SMN protein molecules and a milder version of spinal muscular atrophy (SMA). The finding, a naturally occurring point mutation (a single letter change in the DNA code) in this gene, has immediate implications for genetic testing and possible long-term implications for therapy development.
posted on January 1, 2009 - 3:43pm
QUEST Vol. 16, No. 1
Ms. Wheelchair Michigan spreads message of self-advocacy and inclusion
posted on January 1, 2005 - 3:50pm
Morgan Fritz has a clear idea what her role will be as the 2005 MDA National Goodwill Ambassador. "To talk a lot," she says with a smile. But rest assured: The charming 6-year-old from St. Peters, Mo., knows exactly what to talk about when she and her family represent MDA and its clients nationwide this year. Morgan will attend fund-raisers, sponsor gatherings and other events to spread the word...